Health
Jane Kennedy Named First Patient for New Personalized mRNA Cancer Vaccine Following Landmark Phase 3 Results
Jane Kennedy is set to become the first patient in a new individualized mRNA cancer vaccine program following landmark Phase 3 results from Moderna and Merck involving intismeran autogene in combination with KEYTRUDA.












